Full Press Release Details
Announces First Quarter 2025 Financial Results
RATON, Fla.--(BUSINESS WIRE)-May 13, 2025 -- TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:
TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31,
Quarter 2025 Financial Results
Loss from Continuing Operations
Revenues from Continuing Operations
Operating Expenses from Continuing Operations
of Strategic Alternatives
was previously a women's healthcare company with a mission of creating and commercializing innovative products to support the lifespan
of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty
company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial
press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited
to, statements relating to TherapeuticsMD's objectives, plans and strategies, including the exploration of potential strategic
alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic
transactions, and the completion of such a review process as well as statements, other than historical facts, that address activities,
events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements
are often characterized by terminology such as "believes," "hopes," "may," "anticipates,"
"should," "intends," "plans," "will," "expects," "estimates,"
"projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments
made in light of management's experience and perception of historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press
release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events
or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of
which are outside of the company's control. Important factors that could cause actual results, developments and business decisions
to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's
filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as reports on Form 8-K, and include the following: whether the company's licensees will be successful at commercializing
the products that they licensed and acquired from TherapeuticsMD; whether the company is successful in winding down its operations and
the costs associated therewith, including the company's ability to obtain any additional financing necessary therefor and any adjustments
to the net working capital purchased as part of the Mayne Pharma transaction; whether the company is successful in identifying strategic
pathways to create additional shareholder value; the outcome of the company's disputes with Mayne Pharma; the company's ability
to remain listed on Nasdaq; the impact of product liability lawsuits; the impact of leadership transitions; the impact of Mayne Pharma
Group's agreement to be acquired by Cosette Pharmaceuticals, Inc. and the volatility of the trading price of the company's
Chief Executive Officer
In-Site Communications, Inc.
TherapeuticsMD, Inc.